Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aphthogel is a botanical mucoadhesive film containing licorice (*Glycyrrhiza glabra*) extract, developed by the Isfahan University of Medical Sciences and manufactured by Dr. Saniee Pharmaceutical Company. It is specifically indicated for the treatment and management of radiotherapy-induced oral mucositis in patients with head and neck cancer. The active licorice component functions as a demulcent and anti-inflammatory agent, providing a protective physical barrier over mucosal ulcers while reducing pain and inflammation. Clinical studies have demonstrated its efficacy in reducing the severity of radiation-induced oral mucositis and associated pain, showing comparable or superior results to standard treatments like triamcinolone acetonide films. The film is applied locally to the oral mucosa, where it adheres to provide localized delivery of its botanical active ingredients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aphthogel.